Metropolis HealthcareNSE:METROPOLIS +1.41%95 Net Margin % is 11.99% as of Mar. 2026, which is 22% below its 10-year median of 15.35. GuruFocus rates NSE:METROPOLIS with a GF Score™ of 95/100 and a GF Value™ of ₹588.25 (Fairly Valued). The stock has 4 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Metropolis Healthcare ranks better than 80.39% on this metric.
The historical rank and industry rank for Metropolis Healthcare's Net Margin % or its related term are showing as below:
NSE:METROPOLIS'
s Net Margin % Range Over the Past 10 Years
Min: 10.58 Med: 15.35 Max: 18.66
Current: 11.55
NSE:METROPOLIS's Net Margin % is ranked better than 80.39% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.75
vs NSE:METROPOLIS: 11.55
Metropolis Healthcare (NSE:METROPOLIS) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Metropolis Healthcare Net Margin % Related Terms
Metropolis Healthcare Net Margin % Historical Data
* Premium members only.
The historical data trend for Metropolis Healthcare's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:METROPOLIS vs TMO, DHR, IDXX: Net Margin % Comparison
For the Diagnostics & Research subindustry, Metropolis Healthcare's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Metropolis Healthcare Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Metropolis Healthcare's Net Margin % distribution charts can be found below:
* The bar in red indicates where Metropolis Healthcare's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Metropolis Healthcare (NSE:METROPOLIS) has a Net Margin % of 11.99% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Metropolis Healthcare and its competitors. This is 22% below median its historical median of 15.35. Over the past decade, Metropolis Healthcare's Net Margin % has ranged from 10.58 to 18.66. According to the industry distribution chart, Metropolis Healthcare ranks #40 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 19.6%.
Is Metropolis Healthcare's Net Margin % too high?
Metropolis Healthcare's current Net Margin % of 11.99% is 22% below median its 10-year median of 15.35. Over the past 10 years, this metric has ranged from a low of 10.58 to a high of 18.66. Based on the distribution chart, Metropolis Healthcare ranks #40 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Metropolis Healthcare has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Metropolis Healthcare's Net Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Metropolis Healthcare ranks #40 out of 204 companies for Net Margin %. This places Metropolis Healthcare in the top 20% of its industry — outperforming the majority of peers. Historically, Metropolis Healthcare's own Net Margin % has ranged from 10.58 to 18.66 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Metropolis Healthcare and its competitors. Metropolis Healthcare's current Net Margin % is 11.99%, which is 22% below median its own 10-year median of 15.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metropolis Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Metropolis Healthcare (NSE:METROPOLIS) is currently considered Fairly Valued. The stock's GF Value™ is ₹588.25, compared to a current price of ₹567.95 — trading 3.5% below its estimated fair value. The current Net Margin % is 11.99%, which is 22% below median its 10-year median of 15.35. Metropolis Healthcare's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Metropolis Healthcare (NSE:METROPOLIS), the current Net Margin % is 11.99% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Metropolis Healthcare (NSE:METROPOLIS) Overvalued in 2026?
Based on GuruFocus' analysis, Metropolis Healthcare stock appears to be undervalued.
The current stock price of ₹567.95 is trading 3.5% below its estimated GF Value™ of ₹588.25.
GuruFocus considers Metropolis Healthcare to be Fairly Valued.
Key valuation signals for NSE:METROPOLIS:
Net Margin %: 11.99% (22% below median its 10-year median of 15.35)
GF Value™: ₹588.25 vs. price of ₹567.95 (3.5% below fair value)
No single metric tells the full story. See the NSE:METROPOLIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Metropolis Healthcare Ltd is a diagnostic company in India. It offers a comprehensive range of clinical laboratory tests and profiles, which are used for the prediction, early detection, diagnostic screening, confirmation, and monitoring of the disease. It also offers analytical and supports services to clinical research organizations for their clinical research projects. Pathology service is the only principal activity and reportable segment from which the Group generates its revenue.
95GF Score
Get the complete analysis for NSE:METROPOLIS
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:METROPOLIS has been successfully added to your 
